文献速递头颈与中枢神经肿瘤

胶质母细胞瘤管理:现状与未来方向

Management of glioblastoma: State of the art and future directions.
PubMed 文献 · CA Cancer J Clin · 2020-06-01

胶质母细胞瘤是最常见的恶性原发性脑肿瘤,预后差,中位生存期不足2年。新诊断标准治疗为手术联合替莫唑胺同步放化疗及辅助替莫唑胺,可加用肿瘤电场治疗;复发无标准方案。基于IDH等分子分型的分类更新反映发病机制认识加深,免疫治疗和精准肿瘤学正被积极探索,但血脑屏障和独特微环境构成挑战。

要点

  • 新诊断胶质母细胞瘤标准治疗为手术联合替莫唑胺同步放化疗及辅助替莫唑胺。
  • 肿瘤电场治疗可同步用于辅助替莫唑胺阶段。
  • 复发无标准治疗,可选手术、放疗、化疗或贝伐珠单抗等系统治疗。

核心结论

  • 胶质母细胞瘤预后差,中位生存期不足2年,亟需更有效治疗。
  • 基于分子分型(尤其IDH突变状态)的分类更新反映对发病机制认识加深。

研究设计与样本

  • 本文为综述,总结胶质母细胞瘤当前管理与未来方向。

主要发现

  • 胶质母细胞瘤是最常见恶性原发性脑肿瘤,男性略多,发病率随年龄增加。
  • 新诊断标准治疗包括手术、同步放化疗和辅助替莫唑胺,可加肿瘤电场治疗。
  • 复发时无标准治疗,手术、放疗和系统治疗(化疗或贝伐珠单抗)均为潜在选择。
  • 血脑屏障和独特肿瘤免疫微环境是新型治疗开发的显著挑战。

临床怎么用

  • 新诊断患者按手术联合替莫唑胺同步放化疗及辅助替莫唑胺的标准路径管理。
  • 复发患者根据个体情况选择手术、放疗或系统治疗。
  • 全程重视支持与姑息治疗。

局限性

  • 本文为综述,未提供原始研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approach to therapy in the newly diagnosed setting includes surgery followed by concurrent radiotherapy with temozolomide and further adjuvant temozolomide. Tumor-treating fields, delivering low-intensity alternating electric fields, can also be given concurrently with adjuvant temozolomide. At recurrence, there is no standard of care; however, surgery, radiotherapy, and systemic therapy with chemotherapy or bevacizumab are all potential options, depending on the patient's circumstances. Supportive and palliative care remain important considerations throughout the disease course in the multimodality approach to management. The recently revised classification of glioblastoma based on molecular profiling, notably isocitrate dehydrogenase (IDH) mutation status, is a result of enhanced understanding of the underlying pathogenesis of disease. There is a clear need for better therapeutic options, and there have been substantial efforts exploring immunotherapy and precision oncology approaches. In contrast to other solid tumors, however, biological factors, such as the blood-brain barrier and the unique tumor and immune microenvironment, represent significant challenges in the development of novel therapies. Innovative clinical trial designs with biomarker-enrichment strategies are needed to ultimately improve the outcome of patients with glioblastoma.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Tan AC, Ashley DM, López GY, et al. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020. PMID: 32478924. doi:10.3322/caac.21613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。